Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | NT5E | P21589 | 1/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.75 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25756712 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL7932653 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL314542 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL259446 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL6725190 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL14131245 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL24146779 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL10040218 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL278293 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A | |
| SCHEMBL6934755 | 1.00 | ADORA3 (0.76) | ADORA3LMNANT5EHIF1AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671191-B2 | Methods for preparing 2-alkynyladenosine derivatives | PGX HEALTH, LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADENOSINE THERAPEUTICS, LLC | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177055-A1 | Methods for preparing 2-alkynyladenosine deriviatives | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885LMNA 924/4885NT5E 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.